Relay Therapeutics, INC 10-Q quarterly reports

Relay Therapeutics reported a reduced net loss in Q3 2025 and for the nine months ended September 30, 2025, driven by lower operating expenses and strategic portfolio adjustments, extending its cash runway into 2029.

Relay Therapeutics reported a reduced net loss in Q2 2025, driven by lower R&D and G&A expenses, and extended its cash runway into 2029, despite the termination of its Genentech collaboration.

Relay Therapeutics announces its Q1 2025 financial results, highlighting progress in clinical trials and strategic program prioritization.

Relay Therapeutics reports a net loss of $88.1 million for the third quarter of 2024, while also announcing a strategic shift in its pipeline and plans to seek a commercialization partner for one of its lead assets.

Relay Therapeutics reports a net loss of $92.2 million for the second quarter of 2024, while highlighting progress in clinical trials and discovery programs.

Relay Therapeutics reported a net loss of $81.4 million for the first quarter of 2024, with revenue driven by a milestone payment from the Genentech collaboration.